**Study Overview:** This study checks the long-term safety of two medicines, Deucravacitinib and Ustekinumab, for people with psoriasis, a skin disease that creates red, scaly patches. **Eligibility:** - Participants must have moderate-to-severe plaque psoriasis and be suitable for specific treatments like phototherapy or systemic treatments, including Ustekinumab. - They should have at least one heart-related risk factor such as smoking, high blood pressure (hypertension), high cholesterol (hyperlipidemia), diabetes, obesity, or a family history of heart disease. - Some past heart events that could qualify someone include heart attacks or surgeries like coronary bypass. **Exclusions:** - Anyone with recent heart problems like heart attacks within the last 90 days can't join. - Those with active cancer or past cancer within the last 5 years are also excluded. **Key Points:** - Participants will need regular follow-ups and doctor visits. - The study will check for any safety concerns over a long period. - There is no mention of compensation, so clarify this before joining. Consider if you meet these conditions and discuss with your doctor if this study is right for you.